Propranolol with hormone therapy before surgery for high-risk prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This study tests whether adding propranolol (a blood pressure medicine) to standard hormone therapy before surgery can improve outcomes for men with high-risk prostate cancer. It is for patients who also have mild to moderate high blood pressure.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 85 years old.
- You have high-risk prostate cancer (PSA over 20, Gleason score 8 or higher, or a certain tumor stage) that has not spread to distant parts of the body.
- You have mild to moderate high blood pressure (systolic 140-179 mmHg, diastolic below 110 mmHg).
- You are either not taking blood pressure medication or are on a stable dose of 1-2 blood pressure medications and can switch to propranolol or nifedipine.
- You have not had any previous treatment for prostate cancer.
- You do not have conditions that would make propranolol unsafe, such as asthma, certain heart problems, liver problems, or an underactive thyroid.
- You are able to maintain a good performance status (ECOG 0-1) and give informed consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a drug called homoharringtonine (a type of chemotherapy) to standard hormone therapy before prostate surgery can improve outcomes for men with certain stages of prostate cancer. It's for men who haven't had any previous treatment and plan to have their prostate removed.
This trial tests whether giving hormone therapy (androgen deprivation therapy) before surgery can improve outcomes for men with high-risk prostate cancer. You will receive a special PSMA PET/CT scan to see how the cancer responds.
This trial studies giving hormone treatment and radiation before prostate surgery to treat high-risk, locally advanced prostate cancer. It aims to improve cancer control by shrinking or controlling the tumor before removing it.
This study tests whether a team of doctors, nurses, and other specialists can help reduce the risk of heart problems in men with prostate cancer who are on hormone therapy (ADT). It focuses on providing extra support for heart health.
This trial tests giving a new hormone-blocking drug (darolutamide) plus standard hormone therapy before surgery for men with high-risk prostate cancer that has not spread. The goal is to see if this approach improves outcomes.
This Phase 2 trial studies whether pembrolizumab plus a hormone “androgen axis” blocker taken before prostate surgery can improve outcomes for people with high-risk, non-metastatic prostate cancer. It’s designed for patients who are planning prostate removal with an extended lymph node dissection.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.